PURPOSE: To assess the efficacy, safety, and predictability of the Visian implantable collamer lens with a central port in patients aged between 45 and 55 years. SETTING: Fernández-Vega Ophthalmological Institute, Oviedo, Spain. DESIGN: Retrospective case series. METHODS: Uncorrected (UDVA) and corrected (CDVA) distance visual acuities, refraction, intraocular pressure (IOP), endothelial cell density (ECD), vault, and adverse events over a 1-year period were evaluated retrospectively. RESULTS: A total of 87 eyes (49 patients) were evaluated. The mean postoperative UDVA and CDVA were 0.82 ± 0.24 and 0.93 ± 0.12, respectively. Seventy-eight eyes (approximately 90%) achieved a CDVA of 20/25 or greater. No eye lost 1 or more lines, 53 eyes (60.92%) did not change, 15 eyes (17.24%) gained 1 line, and 19 eyes (21.84%) gained 2 lines or more of CDVA. The efficacy and safety indexes were 0.95 and 1.08, respectively. Seventy-eight eyes (89.65%) were within ±0.50 diopter (D) of the desired sphere refraction, and all eyes (100%) were within ±1.00 D. Fifty eyes (57.7%) showed a spherical equivalent within ±0.13 D. The mean postoperative IOP was 13.58 ± 1.79 mm Hg, and no significant rise (>18 mm Hg) occurred during the follow-up. The largest proportion of eyes (35.63%) reported a reduction in IOP by 1 to 2 mm Hg. Postoperative mean ECD was 2574 ± 362 cells/mm2 (0.41% loss from the preoperative baseline). The mean postoperative vault was 398 ± 187 μm, being the most prevalent range from 201 to 300 μm (22.89% of eyes). No adverse events were reported during the study. CONCLUSIONS: The outcomes reported in this study support the use of this lens in older patients.
PURPOSE: To assess the efficacy, safety, and predictability of the Visian implantable collamer lens with a central port in patients aged between 45 and 55 years. SETTING: Fernández-Vega Ophthalmological Institute, Oviedo, Spain. DESIGN: Retrospective case series. METHODS: Uncorrected (UDVA) and corrected (CDVA) distance visual acuities, refraction, intraocular pressure (IOP), endothelial cell density (ECD), vault, and adverse events over a 1-year period were evaluated retrospectively. RESULTS: A total of 87 eyes (49 patients) were evaluated. The mean postoperative UDVA and CDVA were 0.82 ± 0.24 and 0.93 ± 0.12, respectively. Seventy-eight eyes (approximately 90%) achieved a CDVA of 20/25 or greater. No eye lost 1 or more lines, 53 eyes (60.92%) did not change, 15 eyes (17.24%) gained 1 line, and 19 eyes (21.84%) gained 2 lines or more of CDVA. The efficacy and safety indexes were 0.95 and 1.08, respectively. Seventy-eight eyes (89.65%) were within ±0.50 diopter (D) of the desired sphere refraction, and all eyes (100%) were within ±1.00 D. Fifty eyes (57.7%) showed a spherical equivalent within ±0.13 D. The mean postoperative IOP was 13.58 ± 1.79 mm Hg, and no significant rise (>18 mm Hg) occurred during the follow-up. The largest proportion of eyes (35.63%) reported a reduction in IOP by 1 to 2 mm Hg. Postoperative mean ECD was 2574 ± 362 cells/mm2 (0.41% loss from the preoperative baseline). The mean postoperative vault was 398 ± 187 μm, being the most prevalent range from 201 to 300 μm (22.89% of eyes). No adverse events were reported during the study. CONCLUSIONS: The outcomes reported in this study support the use of this lens in older patients.